Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

Clinical Infectious Diseases

Volumn 33, Issue 5, 2001, Pages 690-699

  Pappas, Peter G ^a   Perfect, John R ^b   Cloud, Gretchen A ^a   Larsen, Robert A ^c   Pankey, George A ^d   Lancaster, Daniel J ^e   Henderson, Harold ^f   Kauffman, Carol A ^g   Haas, David W ^h   Saccente, Michael ⁱ   Hamill, Richard J ^j   Holloway, Melissa S ^a   Warren, Robert M ^a   Dismukes, William E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c LAC USC MEDICAL CENTER   (United States)

^d Oschner Clinic   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CRYPTOCOCCOSIS; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AZOLES; CHILD; CHILD, PRESCHOOL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCONAZOLE; HIV SERONEGATIVITY; HUMANS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035451420     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322597     Document Type: Article

References (33)

1. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis
2. Cryptococcosis, with emphasis on the significance of isolation of Cryptococcus neoformans from the respiratory tract
3. Cryptococcosis
4. Cryptococcal meningitis in patients with AIDS
5. Prognostic factors in cryptococcal meningitis
6. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
7. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks
8. Disseminated cryptococcosis in man: Decreased lymphocyte transformation in response to Cryptococcus neoformans
9. Cell-mediated immunity in cryptococcosis
10. Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection
11. Cryptococcal osteomyelitis and cellular immunodeficiency associated with interleukin-2 deficiency
12. Fluconazole, a new antifungal agent
13. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
14. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
15. Practical guidelines for the management of cryptococcal disease
16. Management of cryptococcosis
17. Nonparametric estimation from incomplete observations
18. Regression models and life-tables
19. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS
20. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
21. Fluconazole treatment of persistent Cryptococcus neoformans prostatic infection in AIDS
22. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: Retrospective analysis of 83 cases
23. Fluconazole monotherapy for cryptococcosis in non-AIDS patents
24. Combination therapy with fluconazole and flucytosine for pulmonary cryptococcosis
25. The evolution of pulmonary cryptococcosis
26. Pulmonary cryptococcosis in patients without HIV infection
27. Pulmonary cryptococcosis: Must all receive amphotericin B?
28. Treatment of cryptococcal meningitis in liver transplantation
29. Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus
30. Infections with Cryptococcus neoformans in an acquired immunodeficiency syndrome
31. Practice guidelines for the management of cryptococcal disease